You are here

  • Home
  • Archive
  • Volume 12, Issue 2
  • A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome
  1. Kamal Naguib Makar Rezkallah1,
  2. Adnan Ahmed1,
  3. Sabah Patel2 and
  4. Kelly Kozma3
  1. 1 Internal Medicine, Presence Saint Joseph Hospital Chicago, Chicago, Illinois, USA
  2. 2 Presence St Joseph Hospital, Chicago, Illinois, USA
  3. 3 Department of Hematology/Oncology, Presence Saint Joseph Hospital Chicago, Chicago, Illinois, USA
  1. Correspondence to Dr Sabah Patel, sabahpatel{at}hotmail.com

Abstract

Panitumumab is a recombinant human IgG2 monoclonal antibody which is used for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or following FOLFIRI (fluoropyrimidine, oxaliplatin and irinotecan) containing chemotherapy regimen. We report a case of an 83-year-old Hispanic man, non-smoker, with KRAS/NRAS wild-type mCRC of the liver who was treated with 9 cycles of FOLFOX4 (fluorouracil, leucovorin and oxaliplatin) and cetuximab. Follow-up abdominal imaging showed progression of CRC, requiring initiation of panitumumab in addition to FOLFIRI. After 2 cycles of this combination chemotherapy, he presented with acute hypoxaemic respiratory failure. Pulmonary imaging showed new onset of interstitial lung disease (ILD). He was treated with systemic corticosteroids with marked improvement of ILD. We aim to highlight the risk of severe life-threatening ILD associated with panitumumab. Early recognition of this serious adverse event helps avoid unnecessary administration of systemic antibiotics and prevent mortality.

  • haematology (drugs and medicines)
  • chemotherapy
  • interstitial Lung Disease
  • cancer intervention

https://doi.org/10.1136/bcr-2018-227785

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors KR: Literature search, research, data acquisition and interpretation and drafting of manuscript. AA: Proof read, data analysis, Literature search, drafting of manuscript. SP: Proof reading, Final Drafting and formatting of manuscript. KZ: Proof Reading, Expert opinion.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.